Vascular Pharma Completes US$16 M Series A Financing and Grants Janssen Biotech Acquisition Option
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 9 (Table of Contents)
Published: 26 Sep-2012
DOI: 10.3833/pdr.v2012.i9.1810 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Vascular Pharmaceuticals has signed an agreement with Johnson & Johnson’s Janssen Biotech that grants Janssen the exclusive right to acquire the North Carolina-based company following the completion of a planned Phase II study of its lead monoclonal antibody drug candidate VPI-2690B for diabetic nephropathy...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS